Thread by @JonahLupton

Several people have asked me why I'm willing to pay 65x sales for $DMTK - it's a good question so here's my answer:

When you find a company like $DMTK that has the potential to grow revenues at 200% annually for the next 4+ years you don't sit back and wait for it to look cheap.

By the time $DMTK looks cheap it might be a $30+ billion company.

You have to adjust your mindset in you want to invest in these hypergrowth companies that have a smaller revenue base now but massive upside thanks to years of insane growth in the future.

Here are my revenue projections for $DMTK based on their current PLA product, Luminate, PLA+ and several other pipeline products:

2021 = $21M+
2022 = $70M+
2023 = $210M+
2024 = $550M+
2025 = $1,000M+

If $DMTK can get to $1+ billion in 2025 this will be a $25+ billion company

If we look at $EXAS revenue growth over the past 5+ years it's similar to what I believe $DMTK can do.

If we look at the chart for $EXAS over the past 5 years, the stock is up more than 2,300%

This is the potential upside for $DMTK and why I'm willing to pay 65x sales in 2021 so that I can capture the next 5+ years of monster gains.

$DMTK is using genomics to revolutionize the skin cancer industry and give people the ability to detect problems earlier than ever before.

Within 5 years the TAM for $DMTK's multiple products will be in the tens of billions of dollars, especially when you think globally.

I could list dozens of companies that looked expensive on a current P/S multiple then turned into massive winners.

If you want to judge a company like $WMT or $GOOG on their current revenues/earnings then that's fine but you need to change your mindset for companies like $DMTK.